Skip to main content

Armata Pharmaceuticals, Inc. (ARMP)

NYSEAMERICAN: ARMP · IEX Real-Time Price · USD
3.64 0.02 (0.41%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap90.65M
Revenue (ttm)3.03M
Net Income (ttm)-24.08M
Shares Out24.76M
EPS (ttm)-1.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,898
Open3.56
Previous Close3.62
Day's Range3.62 - 3.65
52-Week Range2.56 - 10.48
Beta0.15
AnalystsBuy
Price Target7.67 (+111.0%)
Est. Earnings DateNov 11, 2021

About ARMP

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing propriet...

IndustryBiotechnology
CEOTodd Patrick
Employees59
Stock ExchangeNYSEAMERICAN
Ticker SymbolARMP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ARMP stock is "Buy." The 12-month stock price forecast is 7.67, which is an increase of 111.00% from the latest price.

Price Target
$7.67
(111.00% upside)
Analyst Consensus: Buy

News

Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

MARINA DEL REY, Calif., Sept. 8, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...

2 weeks ago - PRNewsWire

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0.00% and 42.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update

MARINA DEL REY, Calif., Aug. 12, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...

1 month ago - PRNewsWire

Will Armata Pharmaceuticals, Inc. (ARMP) Report Negative Q2 Earnings? What You Should Know

Armata Pharmaceuticals, Inc. (ARMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Armata Pharmaceuticals Announces Chief Executive Officer Transition

MARINA DEL REY, Calif., Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific ba...

1 month ago - PRNewsWire

Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference

MARINA DEL REY, Calif. , July 7, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...

2 months ago - PRNewsWire

Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update

MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage th...

4 months ago - PRNewsWire

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Armata Pharmaceuticals Inc. for Potential Breaches ...

NEW YORK, May 13, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cla...

4 months ago - PRNewsWire

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update

MARINA DEL REY, Calif., March 18, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...

6 months ago - PRNewsWire

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva

MARINA DEL REY, Calif., March 17, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...

6 months ago - PRNewsWire

Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

MARINA DEL REY, Calif., March 16, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...

6 months ago - PRNewsWire

Notable Insider Buys Seen In The Past Week: Green Brick, Intel, Teledyne And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

7 months ago - Benzinga

Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Develop...

MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...

7 months ago - PRNewsWire

Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors

MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage t...

9 months ago - PRNewsWire

Armata Pharmaceuticals Announces Third Quarter 2020 Results and Provides General Corporate Update

MARINA DEL REY, Calif., Nov. 12, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted...

10 months ago - PRNewsWire

Armata Pharmaceuticals Issues Letter to Shareholders

MARINA DEL REY, Calif., Oct. 29, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage th...

10 months ago - PRNewsWire

Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development

MARINA DEL REY, Calif., Oct. 26, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage ...

11 months ago - PRNewsWire

Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study

Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.

11 months ago - Zacks Investment Research

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clin...

MARINA DEL REY, Calif., Oct. 15, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage ...

11 months ago - PRNewsWire

Armata Pharmaceuticals to Present at the Virtual 2020 World Antimicrobial Resistance Congress

MARINA DEL REY, Calif., Sept. 29, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage...

11 months ago - PRNewsWire

Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences

MARINA DEL REY, Calif., Sept. 11, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc.

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update

MARINA DEL REY, Calif., Aug. 13, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc.

1 year ago - PRNewsWire